ReviewDrug delivery and translational research2026
Clinical translation of injectable hydrogels: from bioactive polymers to long-acting drug delivery systems.
Review in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Hydrogel coatings for titanium implants: From smart stimuli-responsive strategies to multimodal bone regeneration.Bioactive materials · 2026Review
- SingleInternational journal of oncology · 2026Article
- Hydrogel-Based Depot Systems in Psychiatric Pharmacotherapy: A Narrative Review Rethinking Long-Acting Drug Delivery.Gels (Basel, Switzerland) · 2026Review
- From Infection Control to Tissue Regeneration: Mechanisms, Design Strategies, and Smart Advances in Antibacterial Hydrogels.Gels (Basel, Switzerland) · 2026Review
- Data-Driven Development of Biomedical Hydrogels for Controlled Drug Delivery: Clinical Applications and Emerging Machine-Learning Approaches.Journal of functional biomaterials · 2026Review
- Injectable Thermoresponsive Hydrogels for Localized Drug Delivery: Mechanisms, In Vivo Evidence and Translational Challenges.Journal of functional biomaterials · 2026Review
- Intelligent Hydrocolloid-Based Delivery Systems: Innovations in Pharmacy and Cosmetics.Molecules (Basel, Switzerland) · 2026Review
- Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4.Gels (Basel, Switzerland) · 2026Article
- Musculoskeletal Ultrasound and Protein-Based Hydrogels: Novel Approaches for the Diagnosis and Treatment of Sports Injuries.Polymers · 2026Review
- Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives.Biomarker research · 2026Review
- From Smart Hydrogel Design to 4D-Printed Scaffolds: Emerging Paradigms in Precision Drug Delivery and Regenerative Wound Therapy.Gels (Basel, Switzerland) · 2026Review
- Hydrogel-based strategies for periprosthetic joint infection: from osteoimmune mechanisms to clinical translation.Frontiers in cell and developmental biology · 2026Review
- Engineered Exosomal miRNAs for Post-Stroke Neural Repair: Mechanisms, Delivery Strategies, and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable hydrogels (IHs) have emerged as versatile biomaterials that enable localized therapy through minimally invasive delivery. Their in situ sol-gel transition supports sustained and targeted release of therapeutics, enhancing patient comfort and reducing dosing frequency. However, clinical translation remains limited due to challenges in achieving controlled degradation, ensuring long-term biocompatibility, scaling production, and meeting regulatory standards. Despite these hurdles, several IH-based formulations are progressing through clinical trials or have reached the market, underscoring their therapeutic potential. This review examines the major translational barriers and highlights recent advances that are accelerating the adoption of IHs in precision and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.